Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Osteoarthritis of the Knee Clear all
Terminated No phase listed Observational

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

NCT04349956
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101 or placebo
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
17
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

NCT01709214
View directory record Official record
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

NCT05025787
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-6970, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
40 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2009 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548
View directory record Official record
Conditions
Moderate to Severe Osteoarthritis
Interventions
SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

NCT03028870
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
V120083, Naproxen, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
30
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

NCT00435292
View directory record Official record
Conditions
Osteoarthritis
Interventions
Naproxen, flavocoxid 250 mg, flavocoxid 500 mg
Drug · Dietary Supplement
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
35 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 23, 2026, 10:10 AM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain, Knee
Interventions
Resiniferatoxin, Saline
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Not applicable Interventional

A Biologic Joint Replacement Strategy for Knee Trauma and Post-Traumatic Osteoarthritis

NCT03719417
View directory record Official record
Conditions
Knee Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
Unicompartmental Biologic Arthroplasty, Extensive Biologic Arthroplasty
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

NCT03513016
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
UBX0101, Placebo
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
El Cajon, California • La Mesa, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jul 23, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis

NCT04716803
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Bone Marrow Aspirate Concentrate, Angel Concentrated Platelet Rich Plasma (cPRP) System
Biological · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Jul 23, 2026, 10:10 AM EDT
Withdrawn Not applicable Interventional

Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain

NCT04472091
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Pain Swelling, Knee Arthritis, Arterial Occlusion
Interventions
Genicular artery embolization (GAE)
Device
Lead sponsor
Andrew Picel
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03122860
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
SM04690, Placebo, Sham
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
74
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

NCT02104050
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo Gel, OLT1177 Gel
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Milford, Connecticut • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 23, 2026, 10:10 AM EDT
Active, not recruiting Phase 2 Interventional

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

NCT06865079
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
TPX-100 200mg, Once weekly for 4 weeks, PBS
Drug · Other
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Scottsdale, Arizona • Tucson, Arizona • Carrolton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Not applicable Interventional

An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee

NCT03100799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Arthroscopy, Arthrocentesis, MRI
Procedure · Diagnostic Test
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

NCT03660943
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Placebo, CNTX-4975-05
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 3 Interventional

A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

NCT05603754
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
44
States / cities
Tucson, Arizona • Cerritos, California • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

NCT03182686
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Interventions
4 mL injection of Ampion, 4 mL Injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
13
States / cities
Birmingham, Alabama • Encinitas, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 23, 2026, 10:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

NCT06828666
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo)
Biological · Other
Lead sponsor
Britecyte
Network
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
balicatib (AAE581)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Timeline
Started 2004
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jul 23, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jul 23, 2026, 10:10 AM EDT